Product Name | Epoxomicin |
Description |
Proteasome inhibitor |
Purity | >95% |
CAS No. | 134381-21-8 |
Molecular Formula | C28H50N4O7 |
Molecular Weight | 554.7 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | Soluble in DMSO (15 mg/ml) or dichloromethane:methanol (9:1); insoluble in water. |
Source | Synthetic |
Appearance | White solid |
SMILES | [C@@H](CC)(C)[C@@H](C(N[C@H](C(N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(=O)NCC(=O)[C@]1(C)OC1)CC(C)C)=O)[C@H](CC)C)=O)N(C)C |
InChI | InChI=1S/C28H50N4O7/c1-11-16(5)21(30-27(38)23(17(6)12-2)32(10)19(8)34)25(36)31-22(18(7)33)26(37)29-20(13-15(3)4)24(35)28(9)14-39-28/h15-18,20-23,33H,11-14H2,1-10H3,(H,29,37)(H,30,38)(H,31,36)/t16-,17 |
InChIKey | DOGIDQKFVLKMLQ-JTHVHQAWSA-N |
Safety Phrases |
Classification: Caution. Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection S24/25 - Avoid contact with skin and eyes |
Cite This Product | Epoxomicin (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-388) |
Alternative Names | N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide |
Research Areas | Cell Signaling |
PubChem ID | 11226684 |
Scientific Background | Epoxomicin is a cell permeable, potent and selective proteasome inhibitor originally isolated from Actinomycetes strain based on its potent in vivo antitumor activity. It is a more potent inhibitor of the chymotrypsin-like activity of the proteasome than lactacystin. Epoxomicin also blocks trypsin-like and PGPH activities of the proteasome and regulates antigen presentation at non-toxic doses. It effectively inhibits NF-κB activation in vitro and potently blocks inflammation in vivo in the mouse ear edema assay. The ubiquitin-proteasome system (UPS) and autophagy serve as two complementary, reciprocally regulated protein degradation systems, thus inhibition of UPS by Epoxomicin activates autophagy. |
References |
1. F. Yang, et al. (2009) Neurosci. Lett. 454: 203. 2. K. Ohkawa, et al. (2004) Int. J. Oncol. 24: 425. 3. K. Schwarz, et al. (2000) J. Immunol. 164: 6147. 4. L. Meng, et al. (1999) PNAS. 96: 10403. 5. K.B. Kim, et al. (1999) Bioorg. Med. Chem. Lett. 9: 3335. 6. N. Sin, et al. (1999) Bioorg. Med. Chem. Lett. 9: 2283. 7. M. Hanada, et al. (1992) J. Antibiot. (Tokyo) 45: 1746. |
Reviews
There are no reviews yet.